The European and global potential of carbon dioxide sequestration in tackling climate change

Although, it has received relatively little attention as a potential method of combating climate change in comparison to energy reduction measures and development of carbon-free energy technologies, sequestration of carbon dioxide in geologic or biospheric sinks has enormous potential. This paper reviews the potential for sequestration using geological and ocean storage as a means of reducing carbon dioxide emissions. Considerable quantities of carbon dioxide separated from natural gas deposits and from hydrogen production from steam reforming of methane are already used in enhanced oil recovery and in extraction of coalbed methane, the carbon dioxide remaining sequestered at the end of the process. A number of barriers lie in the way of its implementation on a large scale. There are concerns about possible environmental effects of large-scale injection of carbon dioxide especially into the oceans. Available technologies, especially of separating and capturing the carbon dioxide from waste stream, have high costs at present, perhaps representing an additional 40–100% onto the costs of generating electricity. In most of the world there are no mechanisms to encourage firms to consider sequestration. Considerable R&D is required to bring down the costs of the process, to elucidate the environmental effects of storage and to ensure that carbon dioxide will not escape from stores in unacceptably short timescales. However, the potential of sequestration should not be underestimated as a contribution to global climate change mitigation measures

Environmental emissions of SOFC and SPFC system manufacture and disposal

SIGLEAvailable from British Library Document Supply Centre-DSC:3816.46616(01/00164) / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Concomitant Presence of Hb Agrinio and - -Med Deletion in a Greek Male Patient with Hemoglobinopathy H: More Severe Phenotype and Literature Review

Hemoglobin (Hb) Agrinio is a rare non-deletional a-globin mutation observed almost exclusively in Greek, Spanish or other Mediterranean families. The clinical manifestations of a carrier of a single Hb Agrinio mutation (single heterozygosity) depend on the concomitant presence or absence of other mutations or variants in the beta, alpha or other modifying genes. We present a Greek patient harboring a Hb Agrinio variant plus the - -Med alpha deletional allele, having an infrequent severe form of alpha thalassemia, in contrast to the typical alpha thalassemic patient and requiring regular red blood cell (RBC) transfusions and chelation treatment. We also provide a concise literature review regarding alpha thalassemic hemoglobin variants and their molecular and clinical combinations. A phase 2, double-blind, randomized, placebo-controlled, multicenter clinical trial to determine the efficacy and safety of luspatercept (BMS-986346/ACE-536) for the treatment of anemia in adults with alpha thalassemia with the participation of our center is currently recruiting patients (NCT05664737)